Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.568789 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.568789 34149679!8209490!34149679     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 568789 Nephropedia Template TP {{tp|p=34149679|t=2021. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients |pdf=|usr=}}{{34149679}} gab.com Text Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34149679 #FOAvip Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Talpha1) is used in the management of COVID-19, because it is known to restore the homeostasis of the immune system during infections and cancers. We aim to observe the longitudinal changes in T lymphocyte subsets and to evaluate the efficacy of Talpha1 for COVID-19. A retrospective study was conducted in 275 COVID-19 patients admitted to Shanghai public health clinical center. The clinical and laboratory characteristics between patients with different T lymphocyte phenotypes and those who were and were not treated with Talpha1 were compared. Among the 275 patients, 137 (49.8%) were males, and the median age was 51 years [interquartile range (IQR): 37-64]. A total of 126 patients received Talpha1 therapy and 149 patients did not. There were 158 (57.5%) patients with normal baseline CD4 counts (median:631/muL, IQR: 501~762) and 117 patients (42.5%) with decreased baseline CD4 counts (median:271/muL, IQR: 201~335). In those with decreased baseline CD4 counts, more patients were older (p<0.001), presented as critically ill (p=0.032) and had hypertension (p=0.008) compared with those with normal CD4 counts. There was no statistical difference in the duration of virus shedding in the upper respiratory tract between the two groups (p=0.214). In both the normal (14 vs 11, p=0.028) and the decreased baseline CD4 counts group (15 vs 11, p=0.008), duration of virus clearance in the patients with Talpha1 therapy was significantly longer than that in those without Talpha1 therapy. There was no significant difference in the increase of CD4+ (286 vs 326, p=0.851) and CD8+ T cell (154 vs 170, p=0.842) counts in the recovery period between the two groups with or without Talpha1 therapy. Multivariate linear regression analysis showed that severity of illness (p<0.001) and Talpha1 therapy (p=0.001) were associated with virus clearance. In conclusion, reduction of CD4+ T and CD8+ T cell counts were observed in COVID-19 patients. Talpha1 may have no benefit on restoring CD4+ and CD8+ T cell counts or on the virus clearance. The use of Talpha1 for COVID-19 need to be more fully investigated. Twit Text FOAVip Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34149679 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34149679 #FOAvip English Wikipedia <ref>{{Cite pmid|34149679}}</ref> Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients #MMPMID34149679 Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H Front Immunol 2021[]; 12 (ä): 568789 PMID34149679show ga Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Talpha1) is used in the management of COVID-19, because it is known to restore the homeostasis of the immune system during infections and cancers. We aim to observe the longitudinal changes in T lymphocyte subsets and to evaluate the efficacy of Talpha1 for COVID-19. A retrospective study was conducted in 275 COVID-19 patients admitted to Shanghai public health clinical center. The clinical and laboratory characteristics between patients with different T lymphocyte phenotypes and those who were and were not treated with Talpha1 were compared. Among the 275 patients, 137 (49.8%) were males, and the median age was 51 years [interquartile range (IQR): 37-64]. A total of 126 patients received Talpha1 therapy and 149 patients did not. There were 158 (57.5%) patients with normal baseline CD4 counts (median:631/muL, IQR: 501~762) and 117 patients (42.5%) with decreased baseline CD4 counts (median:271/muL, IQR: 201~335). In those with decreased baseline CD4 counts, more patients were older (p<0.001), presented as critically ill (p=0.032) and had hypertension (p=0.008) compared with those with normal CD4 counts. There was no statistical difference in the duration of virus shedding in the upper respiratory tract between the two groups (p=0.214). In both the normal (14 vs 11, p=0.028) and the decreased baseline CD4 counts group (15 vs 11, p=0.008), duration of virus clearance in the patients with Talpha1 therapy was significantly longer than that in those without Talpha1 therapy. There was no significant difference in the increase of CD4+ (286 vs 326, p=0.851) and CD8+ T cell (154 vs 170, p=0.842) counts in the recovery period between the two groups with or without Talpha1 therapy. Multivariate linear regression analysis showed that severity of illness (p<0.001) and Talpha1 therapy (p=0.001) were associated with virus clearance. In conclusion, reduction of CD4+ T and CD8+ T cell counts were observed in COVID-19 patients. Talpha1 may have no benefit on restoring CD4+ and CD8+ T cell counts or on the virus clearance. The use of Talpha1 for COVID-19 need to be more fully investigated. |*COVID-19 Drug Treatment[MESH] |Adjuvants, Immunologic/pharmacology[MESH] |Adult[MESH] |CD4-Positive T-Lymphocytes/*drug effects[MESH] |CD8-Positive T-Lymphocytes/*drug effects[MESH] |COVID-19/immunology[MESH] |China[MESH] |Female[MESH] |Humans[MESH] |Lymphocyte Count[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T(epmc).pdf DeepDyve Pubget Overpricing